RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0037-1614225
Factor XII Determinations in the Presence and Absence of Phospholipid Antibodies
Publikationsverlauf
Received
10. März 1997
Accepted after resubmission
14. August 1997
Publikationsdatum:
08. Dezember 2017 (online)
Summary
Factor XII (FXII) levels were determined in plasma samples from 29 normal donors, 10 patients with inherited FXII deficiency (all lupus anticoagulant [LA] negative) and 67 LA positive patients, using clotting (FXIIct), chromogenic substrate (FXIIcs) and immunochemical (FXIIag) assays. Excellent correlations were obtained in the three FXII assays with the LA negative samples and between the FXIIcs and FXIIag assays in the LA positive samples. Correlations between both the FXIIcs and FXIIag with FXIIct in the LA positive patients were poor. Of 67 LA positive samples studied, 25 (37.3%) showed lower values in the FXIIct assay; 13 (19.4%) of these patients were pseudo FXII deficient with values of FXII below the lower limit of normal.
These results indicate that a diagnosis of FXII deficiency can be made inappropriately in the presence of phospholipid antibodies and that such a diagnosis should not be made by FXIIct assay alone.
-
References
- 1 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot promoting fraction from plasma. J Clin Invest 1955; 34: 602-13.
- 2 Fuhrer G, Gallimore MJ, Heller W, Hoffmeister H-E. FXII. Blut 1990; 61: 258-66.
- 3 von Kanel R, Wuillemin WA, Furlan M, Lämmle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coag Fibrinol 1992; 3: 555-61.
- 4 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Sem Thromb Haemost 1987; 13: 50-68.
- 5 Levi M, Hack CE, de Boer JP, Brandjes DPM, Büller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. J Clin Invest 1991; 88: 1155-60.
- 6 Winter M, Gallimore MJ, Jones DW. Should factor XII assays be included in thrombophilia screening?. Lancet 1995; 1: 52.
- 7 Halbmayer W-M, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
- 8 Ehrenforth S, Zwinge B, Scharrer I, Bray G. Factor XII deficiency in young people with venous thrombophilia: An analysis of 1554 cases. Blood 1995; 86: 10 (Suppl 1): 879.
- 9 Jones DW, Gallimore MJ, Winter M. Pseudo FXII deficiency and phospholipid antibodies. Thromb Haemost 1996; 75: 696-7.
- 10 Halbmeyer WM, Haushofer A, Angerer V, Fischer M. The discrimination of Factor XII deficiency and lupus anticoagulant. Thromb Haemost 1996; 75: 698-9.
- 11 Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983; 287: 1088-91.
- 12 Jones DW, Gallimore MJ, Winter M. An automated chromogenic peptide substrate assay for factor XII (Hageman factor). Fibrinolysis 1996; 10 (03) 97.
- 13 Loizou S, McRea JD, Rudge AC, Reynolds R, Boyle C, Harris EN. Measurement of anticardiolipin antibodies in an enzyme linked immunosorbant assay: standardisation and quantitation of results. Clin Exp Immunol 1985; 62: 738-45.
- 14 McNally T, Mackie IJ, Isenberg DA, Machin SJ. Immunoelectrophoresis and ELISA techniques for assay of plasma β2 glycoprotein-1 and the influence of plasma lipids. Thromb Res 1993; 72: 275-86.
- 15 Gallimore MJ, Rees WA, Guhrer G, Heller W. A direct chromogenic peptide substrate assay for Hageman factor (FXII). Fibrinolysis 1987; 1: 123-7.
- 16 Jones DW, Gallimore MJ, Winter M, Grant D, Mackie I, Machin S. The incidence of factor XII deficiency in a population of blood donors. Thromb Haemost 1997; 79 (06) 212.
- 17 Jaeger U, Kapiotis S, Papinger I, Puchhammer E, Kyrel P, Lechner K. Transient lupus anticoagulant associated with hypoprothrombinaemia and factor XII deficiency following adenovirus infections. Annals Haematol 1993; 67 (02) 95-9.
- 18 Brookfield C, Malia RG, Cooper SM, Greaves M. Factor XII levels and the lupus anticoagulant. Thromb Haemost 1995; 73 (06) 1441.
- 19 Schousboe I. β2 glycoprotein-1: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
- 20 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2 glycoprotein-1 (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
- 21 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognisable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76 (03) 354-60.